Champions Biotechnology, Inc.
Science & Technology Park at Johns Hopkins
855 North Wolfe Street Suite 619
Baltimore,
MD 21205
United States - Map
Phone: 410-369-0365
Fax: 410-369-0390
Web Site: http://www.championsbiotechnology.com
| Index Membership: | N/A | | Sector: | N/A | | Industry: | N/A | | Full Time Employees: | 11 |
|
| Champions Biotechnology, Inc., a biotechnology company, engages in the development of advanced preclinical platforms and predictive tumor specific data to enhance the value of oncology drugs in the United States. Its preclinical platform is an approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor. The company leverages its preclinical platform to evaluate and develop a portfolio of oncology drug candidates through preclinical trials; and plans to sell, partner or license such drug candidates to pharmaceutical and/or biotechnology companies. It provides Personalized Oncology Services to physicians in the field of oncology by establishing and administering expert medical information panels for their patients to analyze medical records and test results; to assist in understanding conventional and experimental options; and to identify and arrange for testing, analysis, and study of the patientsÂ’ cancer tissues. In addition, the company offers personalized Tumorgraft development and drug studies to physicians for evaluating the effects of cancer therapies on their patientÂ’s. It offers its platform and tumor specific data to other biotechnology and pharmaceutical companies. The company was formerly known as Champions Sports, Inc. and changed its name to Champions Biotechnology, Inc. in January 2007 as a result of change in its business focus towards biotechnology. The company was founded in 1985 and is based in Baltimore, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Douglas D. Burkett Ph.D., 45
Principal Exec. Officer and Pres |
$
225.00K | N/A | Mr. James M. Martell , 62
Founder, Consultant |
$
185.00K | N/A | Mr. Mark Schonau , 52
Chief Financial Officer |
$
53.00K | N/A | Ms. Sara Parkerson RN, MSN, OCN, CCM,
Director of Personalized Oncology Services US |
N/A
| N/A | Dr. Elizabeth Bruckheimer Ph.D.,
Director of Preclinical Devel. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
